Novartis Oral BTK Inhibitor Remibrutinib Cuts Relapse Rate in Phase III MS Trials
Novartis announced on September 2, 2026, positive topline results from the Phase III REMODEL-1/-2 trials evaluating remibrutinib in relapsing multiple sclerosis. Remibrutinib is an oral Bruton's tyrosine kinase inhibitor.
In two Phase III trials involving adult patients with relapsing multiple sclerosis, remibrutinib demonstrated superiority over teriflunomide in reducing the annualized relapse rate and inflammatory brain lesions, while maintaining a favorable safety profile.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is positive for Pharmaceuticals, with intensity 50/100 and 80% confidence over a short term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.